JP2020534812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534812A5 JP2020534812A5 JP2020513724A JP2020513724A JP2020534812A5 JP 2020534812 A5 JP2020534812 A5 JP 2020534812A5 JP 2020513724 A JP2020513724 A JP 2020513724A JP 2020513724 A JP2020513724 A JP 2020513724A JP 2020534812 A5 JP2020534812 A5 JP 2020534812A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- protein
- donor
- regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 68
- 102000039446 nucleic acids Human genes 0.000 claims 66
- 108020004707 nucleic acids Proteins 0.000 claims 66
- 150000007523 nucleic acids Chemical class 0.000 claims 66
- 210000004027 cell Anatomy 0.000 claims 25
- 239000003623 enhancer Substances 0.000 claims 20
- 108091033409 CRISPR Proteins 0.000 claims 19
- 230000004568 DNA-binding Effects 0.000 claims 19
- 230000001105 regulatory effect Effects 0.000 claims 17
- 101710163270 Nuclease Proteins 0.000 claims 15
- 239000003550 marker Substances 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108020004414 DNA Proteins 0.000 claims 13
- 238000003776 cleavage reaction Methods 0.000 claims 13
- 230000007017 scission Effects 0.000 claims 13
- 102000053602 DNA Human genes 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 12
- 230000027455 binding Effects 0.000 claims 12
- 230000003834 intracellular effect Effects 0.000 claims 11
- 108700008625 Reporter Genes Proteins 0.000 claims 9
- 208000009869 Neu-Laxova syndrome Diseases 0.000 claims 8
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 8
- 230000006780 non-homologous end joining Effects 0.000 claims 8
- 238000010354 CRISPR gene editing Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 6
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 108020005004 Guide RNA Proteins 0.000 claims 5
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 4
- 230000005782 double-strand break Effects 0.000 claims 4
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000002372 labelling Methods 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 2
- 101710185494 Zinc finger protein Proteins 0.000 claims 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000006801 homologous recombination Effects 0.000 claims 2
- 238000002744 homologous recombination Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 claims 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 claims 1
- CVRUVYDNRPSKBM-QEJZJMRPSA-N Gln-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N CVRUVYDNRPSKBM-QEJZJMRPSA-N 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 1
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 108091081024 Start codon Proteins 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 239000007801 affinity label Substances 0.000 claims 1
- -1 amino acid amino acids Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000002458 cell surface marker Substances 0.000 claims 1
- 210000003763 chloroplast Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023145587A JP2023168355A (ja) | 2017-09-08 | 2023-09-07 | 改良された相同組換えおよびその組成物のための方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555862P | 2017-09-08 | 2017-09-08 | |
| US62/555,862 | 2017-09-08 | ||
| US201762568661P | 2017-10-05 | 2017-10-05 | |
| US62/568,661 | 2017-10-05 | ||
| US201762574936P | 2017-10-20 | 2017-10-20 | |
| US62/574,936 | 2017-10-20 | ||
| US201862626792P | 2018-02-06 | 2018-02-06 | |
| US62/626,792 | 2018-02-06 | ||
| US201862717403P | 2018-08-10 | 2018-08-10 | |
| US62/717,403 | 2018-08-10 | ||
| PCT/US2018/049966 WO2019051237A1 (en) | 2017-09-08 | 2018-09-07 | ENHANCED RECOMBINANT RECOMBINATION METHODS AND COMPOSITIONS THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145587A Division JP2023168355A (ja) | 2017-09-08 | 2023-09-07 | 改良された相同組換えおよびその組成物のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534812A JP2020534812A (ja) | 2020-12-03 |
| JP2020534812A5 true JP2020534812A5 (https=) | 2021-10-14 |
Family
ID=63714051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513724A Pending JP2020534812A (ja) | 2017-09-08 | 2018-09-07 | 改良された相同組換えおよびその組成物のための方法 |
| JP2023145587A Pending JP2023168355A (ja) | 2017-09-08 | 2023-09-07 | 改良された相同組換えおよびその組成物のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145587A Pending JP2023168355A (ja) | 2017-09-08 | 2023-09-07 | 改良された相同組換えおよびその組成物のための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190119701A1 (https=) |
| EP (1) | EP3679143A1 (https=) |
| JP (2) | JP2020534812A (https=) |
| CN (2) | CN119570864A (https=) |
| WO (1) | WO2019051237A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| ES2817973T3 (es) | 2016-07-01 | 2021-04-08 | Microsoft Technology Licensing Llc | Almacenamiento a través de la edición iterativa del ADN |
| US20180004537A1 (en) | 2016-07-01 | 2018-01-04 | Microsoft Technology Licensing, Llc | Molecular State Machines |
| US11359234B2 (en) | 2016-07-01 | 2022-06-14 | Microsoft Technology Licensing, Llc | Barcoding sequences for identification of gene expression |
| EP3679143A1 (en) | 2017-09-08 | 2020-07-15 | Life Technologies Corporation | Methods for improved homologous recombination and compositions thereof |
| KR102439221B1 (ko) | 2017-12-14 | 2022-09-01 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| EP3781677A4 (en) * | 2018-04-16 | 2022-01-19 | University of Massachusetts | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING |
| US12312584B2 (en) * | 2018-10-02 | 2025-05-27 | Exosome Therapeutics, Inc. | cGMP exosome loaded therapeutics for treating sickle cell disease |
| US20200102563A1 (en) * | 2018-10-02 | 2020-04-02 | Exosome Therapeutics, Inc. | Exosome loaded therapeutics for treating sickle cell disease |
| WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| CN111304248B (zh) * | 2018-12-25 | 2021-08-24 | 百奥赛图江苏基因生物技术有限公司 | 人源化细胞因子il15基因改造非人动物的构建方法及应用 |
| WO2020159470A1 (en) * | 2019-01-28 | 2020-08-06 | Mayo Foundation For Medical Education And Research | Mitochondrial genome editing methods |
| JP7250950B2 (ja) | 2019-03-29 | 2023-04-03 | エフ． ホフマン－ラ ロシュ アーゲー | 所定の構成の複数の発現カセットを標的指向組込みすることによってＦｃＲｎ発現細胞を作製するための方法 |
| AU2020256225B9 (en) * | 2019-04-03 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
| WO2020214610A1 (en) * | 2019-04-16 | 2020-10-22 | Arizona Board Of Regents On Behalf Of Arizona State University | Cas9 fusion proteins and related methods |
| US20220348912A1 (en) * | 2019-06-20 | 2022-11-03 | University Of Massachusetts | Compositions and methods for improved gene editing |
| CA3144106A1 (en) | 2019-07-03 | 2021-01-07 | Integrated Dna Technologies, Inc. | Identification, characterization, and quantitation of crispr-introduced double-stranded dna break repairs |
| US20210079387A1 (en) * | 2019-08-27 | 2021-03-18 | The Jackson Laboratory | Cleavage-resistant donor nucleic acids and methods of use |
| US20220275400A1 (en) * | 2019-08-30 | 2022-09-01 | The Trustees Of Columbia University In The City Of New York | Methods for scalable gene insertions |
| CN119193713A (zh) * | 2019-10-24 | 2024-12-27 | 合成Dna技术公司 | 修饰的双链供体模板 |
| US20230086199A1 (en) * | 2019-11-26 | 2023-03-23 | The Broad Institute, Inc. | Systems and methods for evaluating cas9-independent off-target editing of nucleic acids |
| WO2022214522A2 (en) * | 2021-04-07 | 2022-10-13 | Astrazeneca Ab | Compositions and methods for site-specific modification |
| EP4083227A1 (en) * | 2021-04-29 | 2022-11-02 | 4basebio, S.L.U. | Linear dna with enhanced resistance against exonucleases |
| AU2022343268A1 (en) | 2021-09-08 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| CN115029277B (zh) * | 2022-06-24 | 2023-08-22 | 四川省烟草公司凉山州公司 | 一株耐酸抗青枯病的假蕈状芽孢杆菌 |
| US20260103695A1 (en) * | 2024-02-06 | 2026-04-16 | Integrated Dna Technologies, Inc. | Optimized SPCAS9 Proteins for Efficient Genome Editing in Eukaryotic Cells |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5334575A (en) | 1992-12-17 | 1994-08-02 | Eastman Kodak Company | Dye-containing beads for laser-induced thermal dye transfer |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5888795A (en) | 1997-09-09 | 1999-03-30 | Becton, Dickinson And Company | Thermostable uracil DNA glycosylase and methods of use |
| WO2003012036A2 (en) | 2001-07-27 | 2003-02-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Systems for in vivo site-directed mutagenesis using oligonucleotides |
| HUE030493T2 (en) | 2003-04-04 | 2017-05-29 | Basf Enzymes Llc | Pectate lyases, nucleic acids and processes encoding them for their production and use |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| CA2720903C (en) | 2008-04-14 | 2019-01-15 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| US20120329067A1 (en) | 2010-01-22 | 2012-12-27 | Barbas Iii Carlos F | Methods of Generating Zinc Finger Nucleases Having Altered Activity |
| EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| ES2388020B1 (es) * | 2011-03-10 | 2013-10-01 | Universitat De Girona | Proteínas recombinantes con efecto antitumoral. |
| WO2012168307A2 (en) * | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| WO2013152220A2 (en) | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| EP2840140B2 (en) * | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| WO2014102688A1 (en) | 2012-12-27 | 2014-07-03 | Cellectis | New design matrix for improvement of homology-directed gene targeting |
| US10227610B2 (en) * | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| RU2662932C2 (ru) | 2013-03-14 | 2018-07-31 | Карибо Биосайенсиз, Инк. | Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты |
| US9902973B2 (en) | 2013-04-11 | 2018-02-27 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| DK3456831T3 (da) * | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| EP2796558A1 (en) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| US10787684B2 (en) * | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| KR102170502B1 (ko) * | 2013-12-11 | 2020-10-28 | 리제너론 파마슈티칼스 인코포레이티드 | 게놈의 표적화된 변형을 위한 방법 및 조성물 |
| EP3470089A1 (en) * | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| EP3083958B1 (en) * | 2013-12-19 | 2019-04-17 | Amyris, Inc. | Methods for genomic integration |
| HRP20200529T1 (hr) * | 2014-06-06 | 2020-09-04 | Regeneron Pharmaceuticals, Inc. | Postupci i pripravci za modificiranje ciljnog lokusa |
| SG11201701245QA (en) * | 2014-08-27 | 2017-03-30 | Caribou Biosciences Inc | Methods for increasing cas9-mediated engineering efficiency |
| EP3201340B1 (en) | 2014-10-01 | 2020-12-02 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| US9879283B2 (en) | 2014-10-09 | 2018-01-30 | Life Technologies Corporation | CRISPR oligonucleotides and gene editing |
| WO2016065364A1 (en) | 2014-10-24 | 2016-04-28 | Life Technologies Corporation | Compositions and methods for enhancing homologous recombination |
| EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| US10190106B2 (en) * | 2014-12-22 | 2019-01-29 | Univesity Of Massachusetts | Cas9-DNA targeting unit chimeras |
| CN118271422A (zh) * | 2015-08-28 | 2024-07-02 | 分子传递有限公司 | 转染络合物和其使用方法 |
| WO2017053729A1 (en) | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
| EP3362102A1 (en) * | 2015-10-14 | 2018-08-22 | Life Technologies Corporation | Ribonucleoprotein transfection agents |
| CA2947904A1 (en) | 2015-11-12 | 2017-05-12 | Pfizer Inc. | Tissue-specific genome engineering using crispr-cas9 |
| WO2017096041A1 (en) | 2015-12-02 | 2017-06-08 | The Regents Of The University Of California | Compositions and methods for modifying a target nucleic acid |
| EP3423438A4 (en) * | 2016-03-01 | 2020-05-06 | Molecular Transfer, Inc. | PLANT VIRUS MOTOR PROTEINS AND METHOD FOR USE THEREOF |
| US10428327B2 (en) | 2016-05-27 | 2019-10-01 | Life Technologies Corporation | Compositions and methods for enhancing homologous recombination |
| EP4321623A3 (en) * | 2016-07-15 | 2024-05-15 | Salk Institute for Biological Studies | Methods and compositions for genome editing in non-dividing cells |
| EP3679144A1 (en) * | 2017-09-08 | 2020-07-15 | Life Technologies Corporation | Methods for improved homologous recombination and compositions thereof |
| EP3679143A1 (en) | 2017-09-08 | 2020-07-15 | Life Technologies Corporation | Methods for improved homologous recombination and compositions thereof |
| EP3688159A4 (en) * | 2017-09-26 | 2021-10-20 | The Board of Trustees of the University of Illinois | CRISPR / CAS SYSTEM AND PROCESS FOR GENOME EDITING AND TRANSCRIPT MODULATION |
-
2018
- 2018-09-07 EP EP18779883.0A patent/EP3679143A1/en active Pending
- 2018-09-07 CN CN202411245009.9A patent/CN119570864A/zh active Pending
- 2018-09-07 JP JP2020513724A patent/JP2020534812A/ja active Pending
- 2018-09-07 CN CN201880071907.3A patent/CN111315889A/zh active Pending
- 2018-09-07 US US16/124,931 patent/US20190119701A1/en not_active Abandoned
- 2018-09-07 WO PCT/US2018/049966 patent/WO2019051237A1/en not_active Ceased
-
2023
- 2023-09-07 JP JP2023145587A patent/JP2023168355A/ja active Pending
- 2023-09-29 US US18/374,673 patent/US12612650B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534812A5 (https=) | ||
| CN106011104B (zh) | 利用拆分Cas系统进行基因编辑和表达调控方法 | |
| US11555181B2 (en) | Engineered cascade components and cascade complexes | |
| US11371031B2 (en) | CasZ compositions and methods of use | |
| RU2756865C2 (ru) | Направляемая рнк регуляция транскрипции | |
| JP6718813B2 (ja) | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 | |
| JP2023126956A (ja) | 望ましくないオフターゲット塩基エディター脱アミノ化を制限するためのスプリットデアミナーゼの使用 | |
| US11840694B2 (en) | Truncated CRISPR-Cas proteins for DNA targeting | |
| AU2017335890B2 (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
| JP2024073596A5 (https=) | ||
| CN113373130A (zh) | Cas12蛋白、含有Cas12蛋白的基因编辑系统及应用 | |
| JP2021518139A5 (https=) | ||
| CN103224947A (zh) | 一种基因打靶系统 | |
| CN104080462A (zh) | 用于修饰预定的靶核酸序列的组合物和方法 | |
| DK159976B (da) | Plasmidvektorer, fremgangsmaade til fremstilling deraf, bakterieceller transformeret med plasmidvektorer samt udtrykkelse af protein i transformerede bakterieceller | |
| JP2024536135A (ja) | ＣＲＩＳＰＲ／Ｃａｓ挿入の効率を増大させるための阻害剤の使用 | |
| WO2024251229A1 (zh) | Cas酶及其系统和应用 | |
| WO2023165613A1 (zh) | 5'→3'核酸外切酶在基因编辑系统中的用途和基因编辑系统及其编辑方法 | |
| JP2025502346A (ja) | Ｖｅｇｆを調節する方法およびその使用 | |
| KR20180128864A (ko) | 매칭된 5' 뉴클레오타이드를 포함하는 가이드 rna를 포함하는 유전자 교정용 조성물 및 이를 이용한 유전자 교정 방법 | |
| US20250382598A1 (en) | Cas exonuclease fusion proteins and associated methods for excision, inversion, and site specific integration | |
| WO2024187310A1 (en) | Cas fusion proteins and associated methods for site specific integration | |
| CN119709700A (zh) | 一种靶向范围更广的Cas12f核酸酶及其衍生基因编辑工具 | |
| CN118910006A (zh) | 基于NiCas12b蛋白的CRISPR/Cas12b基因编辑系统及其相关应用 | |
| EP4655394A1 (en) | Variants of cpf1 (cas12a) with improved activity |